Related references
Note: Only part of the references are listed.Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V. T. Catenacci et al.
CANCER DISCOVERY (2021)
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
Fernando Rivera et al.
EUROPEAN JOURNAL OF CANCER (2021)
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group
Ralf-Dieter Hofheinz et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
Ziyu Li et al.
SCIENCE ADVANCES (2020)
p73-NAV3 axis plays a critical role in suppression of colon cancer metastasis
Apoorva Uboveja et al.
ONCOGENESIS (2020)
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers
Jieqiang Zhu et al.
SCIENTIFIC REPORTS (2020)
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
M. J. M. van Velzen et al.
CANCER TREATMENT REVIEWS (2020)
Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
Alissa Greenbaum et al.
CLINICAL COLORECTAL CANCER (2019)
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
Richard C. Turkington et al.
GUT (2019)
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
Alexander M. Frankell et al.
NATURE GENETICS (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Increased Levels of Genomic Instability and Mutations in Homologous Recombination Genes in Locally Advanced Rectal Carcinomas
Luisa Matos do Canto et al.
FRONTIERS IN ONCOLOGY (2019)
NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline
Ryan O. Schenck et al.
BMC BIOINFORMATICS (2019)
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma
Thanos P. Mourikis et al.
NATURE COMMUNICATIONS (2019)
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
T. Ruhstaller et al.
ANNALS OF ONCOLOGY (2018)
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
Michael L. Maitland et al.
BRITISH JOURNAL OF CANCER (2018)
Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up
Raffaello Mancini et al.
CLINICAL COLORECTAL CANCER (2018)
MHC class II restricted neoantigen peptide predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
Weijing Cai et al.
BMC GENOMICS (2018)
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Zehang Jiang et al.
TRANSLATIONAL ONCOLOGY (2018)
Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics
Xiaodun Li et al.
NATURE COMMUNICATIONS (2018)
Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma
Gwendolyn Cramer et al.
JOURNAL OF THORACIC DISEASE (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Elen Kristine Hoglander et al.
GENOME MEDICINE (2018)
A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy
Ayesha Noorani et al.
GENOME RESEARCH (2017)
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
David Cunningham et al.
LANCET ONCOLOGY (2017)
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
Derek Alderson et al.
LANCET ONCOLOGY (2017)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
Juliann E. Kosovec et al.
ONCOTARGET (2017)
Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer
Claudia Wong et al.
JOURNAL OF THORACIC DISEASE (2017)
Oesophageal cancer
Elizabeth C. Smyth et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
F. Noble et al.
BRITISH JOURNAL OF SURGERY (2017)
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial
R. Lesurf et al.
ANNALS OF ONCOLOGY (2017)
8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice
Thomas W. Rice et al.
ANNALS OF CARDIOTHORACIC SURGERY (2017)
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma
Fergus Noble et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET ONCOLOGY (2016)
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Maria Secrier et al.
NATURE GENETICS (2016)
DoCM: a database of curated mutations in cancer
Benjamin J. Ainscough et al.
NATURE METHODS (2016)
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
John M. Findlay et al.
NATURE COMMUNICATIONS (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
Potential biomarkers for esophageal cancer
Cheng Tan et al.
SPRINGERPLUS (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression
Hadas Cohen-Dvashi et al.
EMBO MOLECULAR MEDICINE (2015)
The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
Ryan Charles Pink et al.
GYNECOLOGIC ONCOLOGY (2015)
Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR
Hui Yang et al.
NATURE PROTOCOLS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy
Nirupa Murugaesu et al.
CANCER DISCOVERY (2015)
Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review
Chang-Juan Tao et al.
JOURNAL OF CANCER (2015)
Therapeutic opportunities within the DNA damage response
Laurence H. Pearl et al.
NATURE REVIEWS CANCER (2015)
Response to chemotherapy is not related to chromosome instability in synovial sarcoma
C. Chakiba et al.
ANNALS OF ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis
Katia Nones et al.
NATURE COMMUNICATIONS (2014)
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
Donald Richards et al.
EUROPEAN JOURNAL OF CANCER (2013)
Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis
Emilia Carlsson et al.
GENES CHROMOSOMES & CANCER (2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
Austin M. Dulak et al.
NATURE GENETICS (2013)
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello et al.
NATURE GENETICS (2013)
Pathway-based personalized analysis of cancer
Yotam Drier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Ulrich Ronellenfitsch et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs
Christopher T. Saunders et al.
BIOINFORMATICS (2012)
Potential role of a navigator gene NAV3 in colorectal cancer
E. Carlsson et al.
BRITISH JOURNAL OF CANCER (2012)
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
J. A. Chan et al.
ANNALS OF ONCOLOGY (2011)
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Birgit Luber et al.
BMC CANCER (2011)
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Katrin M. Sjoquist et al.
LANCET ONCOLOGY (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
A flexible R package for nonnegative matrix factorization
Renaud Gaujoux et al.
BMC BIOINFORMATICS (2010)
Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells
Shujie Zhao et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Allele-specific copy number analysis of tumors
Peter Van Loo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
William H. Allum et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Scott L. Carter et al.
NATURE GENETICS (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas
L Milas et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
K Bani-Hani et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
